文献速递心力衰竭与心肌病心律失常

心脏再同步治疗除颤器植入后结局预测:CRT-D Futility评分

Predicting outcome after cardiac resynchronisation therapy defibrillator implantation: the cardiac resynchronisation therapy defibrillator Futility score.
PubMed 文献 · Heart · 2022-07-13

最终模型主要预测因子包括高龄、糖尿病、二尖瓣反流、主动脉瓣狭窄、心衰住院史、肺水肿史、房颤、肾脏病、肝病、营养不良和贫血。CRT-D Futility评分在推导队列AUC为0.716(95%CI 0.698-0.734),验证队列为0.692(95%CI 0.673-0.710),Hosmer-Lemeshow检验P=0.57,提示校准良好;该评分优于Goldenberg和EAARN评分。

要点

  • CRT-D Futility评分可预测预防性CRT-D植入后1年内全因死亡(无效)风险。
  • 评分主要预测因子包括高龄、糖尿病、房颤、心衰住院史、肺水肿史、肾脏病、肝病等。
  • 基于该评分,15.9%患者被归为高风险,其预测无效风险为16.6%。

核心结论

  • CRT-D Futility评分基于全国性大样本队列建立,可能有助于优化医疗决策。
  • 该评分在推导队列和验证队列中均显示出良好的判别能力和校准度。
  • CRT-D Futility评分在识别无效方面优于Goldenberg和EAARN评分。

研究设计与样本

  • 基于法国行政住院出院数据库的回顾性队列研究,纳入2010-2019年所有连续接受预防性CRT-D植入的患者。
  • 采用拆分样本验证法推导并验证CRT-D植入后1年全因死亡(视为无效)的预测模型。

主要发现

  • 共记录7016例死亡(年发病率7.2%),其中1604例(22.8%)发生在CRT-D植入后1年内。
  • CRT-D Futility评分AUC在推导队列为0.716(95%CI 0.698-0.734),在验证队列为0.692(95%CI 0.673-0.710)。
  • Hosmer-Lemeshow检验P值为0.57,提示校准准确。
  • 基于CRT-D Futility评分,15.9%的患者被归类为高风险(预测无效风险为16.6%)。

关键数值与推荐

  • CRT-D Futility评分高风险组(15.9%的患者)预测的1年无效风险为16.6%。
  • 推导队列AUC为0.716(95%CI 0.698-0.734),验证队列AUC为0.692(95%CI 0.673-0.710)。
  • Hosmer-Lemeshow检验P=0.57,提示模型校准良好。

临床怎么用

  • CRT-D Futility评分可用于识别预防性CRT-D植入后1年内死亡风险高的患者,辅助临床决策。
  • 对于评分高风险患者,可考虑优化或重新评估CRT-D植入策略。

局限性

  • 研究基于行政住院数据库,可能存在编码偏倚和未测量的混杂因素。
  • 研究为回顾性设计,结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk-benefit for cardiac resynchronisation therapy (CRT) defibrillator (CRT-D) over CRT pacemaker remains a matter of debate. We aimed to identify patients with a poor outcome within 1 year of CRT-D implantation, and to develop a CRT-D Futility score. METHODS: Based on an administrative hospital-discharge database, all consecutive patients treated with prophylactic CRT-D implantation in France (2010-2019) were included. A prediction model was derived and validated for 1-year all-cause death after CRT-D implantation (considered as futility) by using split-sample validation. RESULTS: Among 23 029 patients (mean age 68±10 years; 4873 (21.2%) women), 7016 deaths were recorded (yearly incidence rate 7.2%), of which 1604 (22.8%) occurred within 1 year of CRT-D implantation. In the derivation cohort (n=11 514), the final logistic regression model included-as main predictors of futility-older age, diabetes, mitral regurgitation, aortic stenosis, history of hospitalisation with heart failure, history of pulmonary oedema, atrial fibrillation, renal disease, liver disease, undernutrition and anaemia. Area under the curve for the CRT-D Futility score was 0.716 (95% CI: 0.698 to 0.734) in the derivation cohort and 0.692 (0.673 to 0.710) in the validation cohort. The Hosmer-Lemeshow test had a p-value of 0.57 suggesting accurate calibration. The CRT-D Futility score outperformed the Goldenberg and EAARN scores for identifying futility. Based on the CRT-D Futility score, 15.9% of these patients were categorised at high risk (predicted futility of 16.6%). CONCLUSIONS: The CRT-D Futility score, established from a large nationwide cohort of patients treated with CRT-D, may be a relevant tool for optimising healthcare decision-making.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Maille B, Bodin A, Bisson A, et al. Predicting outcome after cardiac resynchronisation therapy defibrillator implantation: the cardiac resynchronisation therapy defibrillator Futility score. Heart. 2022. PMID: 35410895. doi:10.1136/heartjnl-2021-320532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。